)
Sohini Das writes on automobile and healthcare sectors for Business Standard. Over her 17 years as a journalist, she has covered multiple sectors and issues -- FMCG, dairy, tourism, and state elections, among others, across Kolkata, Ahmedabad, and Mumbai. She loves doing personality stories and ground reportage.
Sohini Das writes on automobile and healthcare sectors for Business Standard. Over her 17 years as a journalist, she has covered multiple sectors and issues -- FMCG, dairy, tourism, and state elections, among others, across Kolkata, Ahmedabad, and Mumbai. She loves doing personality stories and ground reportage.
The government is in the final stages of due diligence to ink a supply deal with Serum Institute of India and Bharat Biotech, which have got approval for emergency use of their vaccines
Government has asked airlines to get ready to transport 30 tonnes of vaccines immediately
More than 5,000 people have been given both shots of the vaccine; efficacy data around March
The final contract is expected to be signed soon
Clocks 8.5% growth in December, up sharply from November's 1% due to revival in volume growth
Bharat Biotech is currently working on two intra-nasal vaccines
Adar Poonawalla and Krishna Ella issue joint statement saying they would work together to roll out Covid-19 vaccine
Minutes of expert panel meeting made public
Krishna Ella turns the tables on critics, questions approval granted to Oxford-Astra vaccine
MRP for private market Rs 1,000/ dose; current licence does not allow export or sale in private market
While the Oxford-AstraZeneca vaccine made by Serum Institute here has 70.42% efficacy, Bharat Biotech's still does not have efficacy data as trials are underway in India
It took a chance by ramping up capacity on vaccines when they were yet to be approved and is set to emerge a global winner
Bharat Biotech's Covaxin is based on a whole inactivated virus platform, an old technology which is used to make vaccines given to infants
However, he said that many countries, especially the European Union, are likely to step up production and increase their portfolios in an attempt to reduce import reliability.
India would need 30 million doses in the first phase when it vaccinates the essential services workers including health care professionals, municipal and police staff, etc
US giant Pfizer did not come to present its case on Friday before the Subject Expert Committee
Suresh Jadhav, executive director of the Pune-based firm, said on Friday Serum was seeking approval from the Drug Controller General of India (DCGI) for the two-full dose regimen
Advice comes from Centre; some states begin talks with pharma firms
Most firms plan to increase capacity to meet fresh orders
Bharat Biotech had recently sought an accelerated approval from the regulator based on phase 1 and phase 2 studies